Literature DB >> 22149402

Co-morbidity in mild-to-moderate COPD: comparison to normal and restrictive lung function.

Anne Lindberg1, Lars-Gunnar Larsson, Eva Rönmark, Bo Lundbäck.   

Abstract

BACKGROUND: A relationship between local and systemic inflammation and different co-morbidities, such as cardiovascular, has been discussed in relation to disease process and prognosis in COPD. AIM: To evaluate if conditions as cardiovascular diseases, diabetes, chronic rhinitis and gastroesophageal reflux are overrepresented in COPD.
METHODS: All subjects with COPD according to GOLD, FEV(1)/FVC<0.70, were identified (n = 993) from the clinical follow-up in 2002-04 of the OLIN (Obstructive Lung Disease in Northern Sweden) studies' cohorts together with 993 gender- and age-matched reference subjects without COPD (non-COPD, further divided into normal and restrictive lung function). Interview data on co-morbidity and symptoms were used.
RESULTS: Cardiovascular co-morbidity, taken together heart disease, hypertension, stroke and intermittent claudication, was the most common and higher in COPD compared to in normal lung function (Nlf) 50.1% vs 41.0% (p<0.001). The prevalence of chronic rhinitis and gastroesophageal reflux (GERD) was higher in COPD compared to in Nlf (43.1% vs 32.3%, p<0.001 and 16.7% vs 12.0%, p = 0.011). In restrictive lung function the prevalence of chronic rhinitis, cardiovascular disease, hyperlipemia and diabetes was higher compared to in Nlf (41.0% vs 32.3%, p = 0.017, 59.0% vs 41.0%, p<0.001, 29.2% vs.12.9%, p = 0.033, 20.9% vs 8.6%, p <0.001). In COPD and heart disease, 62.5% had chronic rhinitis and/or GERD, while in Nlf the corresponding proportion was 42.5%.
CONCLUSION: Co-morbid conditions such as cardiovascular disease, chronic rhinitis and gastroesophageal reflux were common in COPD. The overlap between heart disease, chronic rhinitis and GERD was large in COPD. Restrictive lung function did also identify a population with increased disease burden.

Entities:  

Mesh:

Year:  2011        PMID: 22149402     DOI: 10.3109/15412555.2011.629858

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  21 in total

1.  Pathophysiology of Gastroesophageal Reflux in Patients with Chronic Pulmonary Obstructive Disease Is Linked to an Increased Transdiaphragmatic Pressure Gradient and not to a Defective Esophagogastric Barrier.

Authors:  Leonardo M Del Grande; Fernando A M Herbella; Amilcar M Bigatao; Henrique Abrao; Jose R Jardim; Marco G Patti
Journal:  J Gastrointest Surg       Date:  2015-09-24       Impact factor: 3.452

2.  Hyperinsulinemia adversely affects lung structure and function.

Authors:  Suchita Singh; Manish Bodas; Naveen K Bhatraju; Bijay Pattnaik; Atish Gheware; Praveen Kolumam Parameswaran; Michael Thompson; Michelle Freeman; Ulaganathan Mabalirajan; Reinoud Gosens; Balaram Ghosh; Christina Pabelick; Allan Linneberg; Y S Prakash; Anurag Agrawal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-02-26       Impact factor: 5.464

3.  The lung tissue microbiome in chronic obstructive pulmonary disease.

Authors:  Marc A Sze; Pedro A Dimitriu; Shizu Hayashi; W Mark Elliott; John E McDonough; John V Gosselink; Joel Cooper; Don D Sin; William W Mohn; James C Hogg
Journal:  Am J Respir Crit Care Med       Date:  2012-03-15       Impact factor: 21.405

Review 4.  Defining COPD-Related Comorbidities, 2004-2014.

Authors:  Carlos H Martinez; David M Mannino; Miguel J Divo
Journal:  Chronic Obstr Pulm Dis       Date:  2014-05-06

5.  Incidence of stroke and stroke subtypes in chronic obstructive pulmonary disease.

Authors:  Martin Söderholm; Malin Inghammar; Bo Hedblad; Arne Egesten; Gunnar Engström
Journal:  Eur J Epidemiol       Date:  2015-12-28       Impact factor: 8.082

Review 6.  Chronic Obstructive Pulmonary Disease and the Risk of Stroke.

Authors:  Ann D Morgan; Chetna Sharma; Kieran J Rothnie; James Potts; Liam Smeeth; Jennifer K Quint
Journal:  Ann Am Thorac Soc       Date:  2017-05

Review 7.  Should mild COPD be treated? Evidence for early pharmacological intervention.

Authors:  Amany F Elbehairy; Katherine A Webb; J Alberto Neder; J Alberto Neder; Denis E O'Donnell
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

8.  Chronic obstructive pulmonary disease, hospital visits, and comorbidities: National Survey of Residential Care Facilities, 2010.

Authors:  Anne G Wheaton; Earl S Ford; Timothy J Cunningham; Janet B Croft
Journal:  J Aging Health       Date:  2014-10-05

Review 9.  New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses.

Authors:  Douglas W Mapel; Melissa H Roberts
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

10.  Prescribing optimal nutrition and physical activity as "first-line" interventions for best practice management of chronic low-grade inflammation associated with osteoarthritis: evidence synthesis.

Authors:  Elizabeth Dean; Rasmus Gormsen Hansen
Journal:  Arthritis       Date:  2012-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.